Relmada Therapeutics CNS Treatment 2024 Investor Presentation

Relmada Therapeutics presents its lead program REL-1017, a novel NMDAR antagonist in Phase 3 trials as adjunctive treatment for major depressive disorder. The company highlights clinical expertise, expanding therapeutic portfolio including a psilocybin program, and efficacy/safety profiles addressing unmet needs in MDD treatment.